PDCD1 and pancreatic neoplasm: It has been observed in bilateral, syngeneic models of colorectal and pancreatic cancer that a variant of OBP-301 in combination with an antibody targeting programmed cell death protein-1 (PD-1) yielded an abscopal effect on non-treated tumors confirming that oAds are promising agents to immunize tumors for checkpoint inhibitors [52].